Moreover, overall survival was significantly improved in the SAR with anti-E3–anti-CD33 treatment group compared to SAR with anti-E3–anti-CD19 (i.e., non-AML targeting) treatment group in both MV4-11 (p = 0.009) and THP-1 (p = 0.010) models (Fig. 5B, F). The gene discussed is CD19; the disease is acute myeloid leukemia.